Avalo Therapeutics, Inc. (AVTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 49/100 (MEDIUM), 110.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 28.38% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
- Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
- Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
- Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
- Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Avalo Therapeutics, Inc..
Full AVTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.